Advertisement
U.S. markets close in 5 hours 14 minutes

aTyr Pharma, Inc. (LIFE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.7350-0.0250 (-1.42%)
As of 10:45AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.7600
Open1.7400
Bid1.7000 x 200
Ask1.7700 x 400
Day's Range1.7100 - 1.7500
52 Week Range1.0800 - 2.7000
Volume46,258
Avg. Volume559,080
Market Cap117.546M
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-0.9400
Earnings DateMay 07, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LIFE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • aTyr Pharma, Inc.
    Analyst Report: Bristol-Myers Squibb Co.Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    aTyr Pharma to Participate in April Investor Conferences

    SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024. Details of the conferences appear below: Conference: Evercore ISI Diamonds in the Rough Webinar DayDate: Thursday, April 4, 2024 Time: 10:3

  • InvestorPlace

    3 Penny Stocks That Could Be Multibaggers in the Making: March Edition

    When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we’re done here, right? Of course, human nature being what it is, people are going to place wagers. Fundamentally, the issue with penny stocks is that this segment really blurs the line between investment and legalized gambling. More often than not, people lose their shirts in this corridor of the equities market. You’ve got to heed the warnings before you participate. Nevertheless, the one aspec

  • Simply Wall St.

    aTyr Pharma Full Year 2023 Earnings: Revenues Disappoint

    aTyr Pharma ( NASDAQ:LIFE ) Full Year 2023 Results Key Financial Results Net loss: US$50.4m (loss widened by 11% from...